XTSXKNE
Market cap9mUSD
Dec 24, Last price
0.10CAD
1D
5.26%
1Q
-25.93%
Jan 2017
-33.33%
Name
Kane Biotech Inc
Chart & Performance
Profile
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 149 -94.42% | 2,668 65.97% | 1,608 19.84% | |||||||
Cost of revenue | 3,739 | 6,032 | 6,491 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (3,590) | (3,364) | (4,884) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 1,143 | 495 | ||||||||
Tax Rate | ||||||||||
NOPAT | (3,590) | (4,507) | (5,378) | |||||||
Net income | (5,034) 29.41% | (3,890) -15.52% | (4,605) 23.89% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 416 | 974 | 1,116 | |||||||
BB yield | -4.09% | -8.96% | -6.19% | |||||||
Debt | ||||||||||
Debt current | 7,084 | 4,278 | 2,512 | |||||||
Long-term debt | 3,159 | 3,666 | 3,424 | |||||||
Deferred revenue | 191 | 837 | 777 | |||||||
Other long-term liabilities | 829 | |||||||||
Net debt | 9,493 | 6,395 | 3,793 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (3,222) | (3,043) | (2,289) | |||||||
CAPEX | (9) | (88) | (354) | |||||||
Cash from investing activities | (116) | (108) | (374) | |||||||
Cash from financing activities | 2,982 | 3,103 | 2,808 | |||||||
FCF | (3,316) | (4,323) | (6,285) | |||||||
Balance | ||||||||||
Cash | 749 | 1,105 | 1,153 | |||||||
Long term investments | 444 | 989 | ||||||||
Excess cash | 742 | 1,416 | 2,062 | |||||||
Stockholders' equity | (16,158) | (11,582) | (7,073) | |||||||
Invested Capital | 18,029 | 15,139 | 10,998 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 127,120 | 120,702 | 112,600 | |||||||
Price | 0.08 -11.11% | 0.09 -43.75% | 0.16 14.29% | |||||||
Market cap | 10,170 -6.38% | 10,863 -39.70% | 18,016 19.65% | |||||||
EV | 21,812 | 19,643 | 24,128 | |||||||
EBITDA | (3,352) | (3,100) | (4,696) | |||||||
EV/EBITDA | ||||||||||
Interest | 1,215 | 822 | 416 | |||||||
Interest/NOPBT |